Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia

Brunangelo Falini, Maria Paola Martelli, Niccolò Bolli, Rossella Bonasso, Emanuela Ghia, Maria Teresa Pallotta, Daniela Diverio, Ildo Nicoletti, Roberta Pacini, Alessia Tabarrini, Barbara Verducci Galletti, Roberta Mannucci, Giovanni Roti, Roberto Rosati, Giorgina Specchia, Arcangelo Liso, Enrico Tiacci, Myriam Alcalay, Lucilla Luzi, Sara VolorioLoris Bernard, Anna Guarini, Sergio Amadori, Franco Mandelli, Fabrizio Pane, Francesco Lo-Coco, Giuseppe Saglio, Pier Giuseppe Pelicci, Massimo F. Martelli, Cristina Mecucci

Research output: Contribution to journalArticle

Abstract

Nucleophosmin (NPM) exon-12 mutations occur in 50% to 60% of adult acute myeloid leukemia (AML) with normal karyotype and are predictors of favorable prognosis. We evaluated bone marrow or peripheral blood samples from 450 adult patients with AML of the GIMEMA(Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto)/AML12 EORTC (European Organization for Research and Treatment of Cancer) trial to (1) search for new exon-12 NPM mutations; (2) determine whether NPM immunostaining on paraffin-embedded biopsies predicts NPM mutations; and (3) investigate altered nucleocytoplasmic NPM traffic in primary AML cells. Fourteen NPM mutations, including 8 new variants, were identified. All 200 AML cases expressing cytoplasmic NPM (NPMc+ AML) carried NPM mutations. None of the 250 cases with nucleus-restricted NPM (NPMc- AML) was mutated. At the C-terminus, NPM leukemic mutants carried mutations of only tryptophan 290 or of both tryptophans 288 and 290 and a new nuclear export signal (NES) motif, which appear to underlie their nuclear export. The specific Crm1/exportin-1 inhibitor leptomycin-B relocated NPM mutants from cytoplasm to nucleus of primary NPMc+ AML cells, demonstrating that nuclear export is NES dependent. NPM mutants bound and recruited wildtype NPM into leukemic cell cytoplasm. Because alterations at C-terminus of leukemic NPM mutants are similar, immunohistochemistry detects all exon-12 NPM mutations and is a valuable, inexpensive tool in the diagnostic-prognostic work-up of patients with AML with normal karyotype.

Original languageEnglish
Pages (from-to)1999-2005
Number of pages7
JournalBlood
Volume108
Issue number6
DOIs
Publication statusPublished - Sep 15 2006

Fingerprint

Acute Myeloid Leukemia
Immunohistochemistry
Mutation
Nuclear Export Signals
Exons
Cell Nucleus Active Transport
nucleophosmin
Myeloid Cells
Karyotype
Tryptophan
Cytoplasm
Biopsy
Paraffin
Bone
Blood
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

Falini, B., Martelli, M. P., Bolli, N., Bonasso, R., Ghia, E., Pallotta, M. T., ... Mecucci, C. (2006). Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood, 108(6), 1999-2005. https://doi.org/10.1182/blood-2006-03-007013

Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. / Falini, Brunangelo; Martelli, Maria Paola; Bolli, Niccolò; Bonasso, Rossella; Ghia, Emanuela; Pallotta, Maria Teresa; Diverio, Daniela; Nicoletti, Ildo; Pacini, Roberta; Tabarrini, Alessia; Galletti, Barbara Verducci; Mannucci, Roberta; Roti, Giovanni; Rosati, Roberto; Specchia, Giorgina; Liso, Arcangelo; Tiacci, Enrico; Alcalay, Myriam; Luzi, Lucilla; Volorio, Sara; Bernard, Loris; Guarini, Anna; Amadori, Sergio; Mandelli, Franco; Pane, Fabrizio; Lo-Coco, Francesco; Saglio, Giuseppe; Pelicci, Pier Giuseppe; Martelli, Massimo F.; Mecucci, Cristina.

In: Blood, Vol. 108, No. 6, 15.09.2006, p. 1999-2005.

Research output: Contribution to journalArticle

Falini, B, Martelli, MP, Bolli, N, Bonasso, R, Ghia, E, Pallotta, MT, Diverio, D, Nicoletti, I, Pacini, R, Tabarrini, A, Galletti, BV, Mannucci, R, Roti, G, Rosati, R, Specchia, G, Liso, A, Tiacci, E, Alcalay, M, Luzi, L, Volorio, S, Bernard, L, Guarini, A, Amadori, S, Mandelli, F, Pane, F, Lo-Coco, F, Saglio, G, Pelicci, PG, Martelli, MF & Mecucci, C 2006, 'Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia', Blood, vol. 108, no. 6, pp. 1999-2005. https://doi.org/10.1182/blood-2006-03-007013
Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006 Sep 15;108(6):1999-2005. https://doi.org/10.1182/blood-2006-03-007013
Falini, Brunangelo ; Martelli, Maria Paola ; Bolli, Niccolò ; Bonasso, Rossella ; Ghia, Emanuela ; Pallotta, Maria Teresa ; Diverio, Daniela ; Nicoletti, Ildo ; Pacini, Roberta ; Tabarrini, Alessia ; Galletti, Barbara Verducci ; Mannucci, Roberta ; Roti, Giovanni ; Rosati, Roberto ; Specchia, Giorgina ; Liso, Arcangelo ; Tiacci, Enrico ; Alcalay, Myriam ; Luzi, Lucilla ; Volorio, Sara ; Bernard, Loris ; Guarini, Anna ; Amadori, Sergio ; Mandelli, Franco ; Pane, Fabrizio ; Lo-Coco, Francesco ; Saglio, Giuseppe ; Pelicci, Pier Giuseppe ; Martelli, Massimo F. ; Mecucci, Cristina. / Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. In: Blood. 2006 ; Vol. 108, No. 6. pp. 1999-2005.
@article{6f3f418185364f15835fec06ffbc3d94,
title = "Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia",
abstract = "Nucleophosmin (NPM) exon-12 mutations occur in 50{\%} to 60{\%} of adult acute myeloid leukemia (AML) with normal karyotype and are predictors of favorable prognosis. We evaluated bone marrow or peripheral blood samples from 450 adult patients with AML of the GIMEMA(Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto)/AML12 EORTC (European Organization for Research and Treatment of Cancer) trial to (1) search for new exon-12 NPM mutations; (2) determine whether NPM immunostaining on paraffin-embedded biopsies predicts NPM mutations; and (3) investigate altered nucleocytoplasmic NPM traffic in primary AML cells. Fourteen NPM mutations, including 8 new variants, were identified. All 200 AML cases expressing cytoplasmic NPM (NPMc+ AML) carried NPM mutations. None of the 250 cases with nucleus-restricted NPM (NPMc- AML) was mutated. At the C-terminus, NPM leukemic mutants carried mutations of only tryptophan 290 or of both tryptophans 288 and 290 and a new nuclear export signal (NES) motif, which appear to underlie their nuclear export. The specific Crm1/exportin-1 inhibitor leptomycin-B relocated NPM mutants from cytoplasm to nucleus of primary NPMc+ AML cells, demonstrating that nuclear export is NES dependent. NPM mutants bound and recruited wildtype NPM into leukemic cell cytoplasm. Because alterations at C-terminus of leukemic NPM mutants are similar, immunohistochemistry detects all exon-12 NPM mutations and is a valuable, inexpensive tool in the diagnostic-prognostic work-up of patients with AML with normal karyotype.",
author = "Brunangelo Falini and Martelli, {Maria Paola} and Niccol{\`o} Bolli and Rossella Bonasso and Emanuela Ghia and Pallotta, {Maria Teresa} and Daniela Diverio and Ildo Nicoletti and Roberta Pacini and Alessia Tabarrini and Galletti, {Barbara Verducci} and Roberta Mannucci and Giovanni Roti and Roberto Rosati and Giorgina Specchia and Arcangelo Liso and Enrico Tiacci and Myriam Alcalay and Lucilla Luzi and Sara Volorio and Loris Bernard and Anna Guarini and Sergio Amadori and Franco Mandelli and Fabrizio Pane and Francesco Lo-Coco and Giuseppe Saglio and Pelicci, {Pier Giuseppe} and Martelli, {Massimo F.} and Cristina Mecucci",
year = "2006",
month = "9",
day = "15",
doi = "10.1182/blood-2006-03-007013",
language = "English",
volume = "108",
pages = "1999--2005",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia

AU - Falini, Brunangelo

AU - Martelli, Maria Paola

AU - Bolli, Niccolò

AU - Bonasso, Rossella

AU - Ghia, Emanuela

AU - Pallotta, Maria Teresa

AU - Diverio, Daniela

AU - Nicoletti, Ildo

AU - Pacini, Roberta

AU - Tabarrini, Alessia

AU - Galletti, Barbara Verducci

AU - Mannucci, Roberta

AU - Roti, Giovanni

AU - Rosati, Roberto

AU - Specchia, Giorgina

AU - Liso, Arcangelo

AU - Tiacci, Enrico

AU - Alcalay, Myriam

AU - Luzi, Lucilla

AU - Volorio, Sara

AU - Bernard, Loris

AU - Guarini, Anna

AU - Amadori, Sergio

AU - Mandelli, Franco

AU - Pane, Fabrizio

AU - Lo-Coco, Francesco

AU - Saglio, Giuseppe

AU - Pelicci, Pier Giuseppe

AU - Martelli, Massimo F.

AU - Mecucci, Cristina

PY - 2006/9/15

Y1 - 2006/9/15

N2 - Nucleophosmin (NPM) exon-12 mutations occur in 50% to 60% of adult acute myeloid leukemia (AML) with normal karyotype and are predictors of favorable prognosis. We evaluated bone marrow or peripheral blood samples from 450 adult patients with AML of the GIMEMA(Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto)/AML12 EORTC (European Organization for Research and Treatment of Cancer) trial to (1) search for new exon-12 NPM mutations; (2) determine whether NPM immunostaining on paraffin-embedded biopsies predicts NPM mutations; and (3) investigate altered nucleocytoplasmic NPM traffic in primary AML cells. Fourteen NPM mutations, including 8 new variants, were identified. All 200 AML cases expressing cytoplasmic NPM (NPMc+ AML) carried NPM mutations. None of the 250 cases with nucleus-restricted NPM (NPMc- AML) was mutated. At the C-terminus, NPM leukemic mutants carried mutations of only tryptophan 290 or of both tryptophans 288 and 290 and a new nuclear export signal (NES) motif, which appear to underlie their nuclear export. The specific Crm1/exportin-1 inhibitor leptomycin-B relocated NPM mutants from cytoplasm to nucleus of primary NPMc+ AML cells, demonstrating that nuclear export is NES dependent. NPM mutants bound and recruited wildtype NPM into leukemic cell cytoplasm. Because alterations at C-terminus of leukemic NPM mutants are similar, immunohistochemistry detects all exon-12 NPM mutations and is a valuable, inexpensive tool in the diagnostic-prognostic work-up of patients with AML with normal karyotype.

AB - Nucleophosmin (NPM) exon-12 mutations occur in 50% to 60% of adult acute myeloid leukemia (AML) with normal karyotype and are predictors of favorable prognosis. We evaluated bone marrow or peripheral blood samples from 450 adult patients with AML of the GIMEMA(Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto)/AML12 EORTC (European Organization for Research and Treatment of Cancer) trial to (1) search for new exon-12 NPM mutations; (2) determine whether NPM immunostaining on paraffin-embedded biopsies predicts NPM mutations; and (3) investigate altered nucleocytoplasmic NPM traffic in primary AML cells. Fourteen NPM mutations, including 8 new variants, were identified. All 200 AML cases expressing cytoplasmic NPM (NPMc+ AML) carried NPM mutations. None of the 250 cases with nucleus-restricted NPM (NPMc- AML) was mutated. At the C-terminus, NPM leukemic mutants carried mutations of only tryptophan 290 or of both tryptophans 288 and 290 and a new nuclear export signal (NES) motif, which appear to underlie their nuclear export. The specific Crm1/exportin-1 inhibitor leptomycin-B relocated NPM mutants from cytoplasm to nucleus of primary NPMc+ AML cells, demonstrating that nuclear export is NES dependent. NPM mutants bound and recruited wildtype NPM into leukemic cell cytoplasm. Because alterations at C-terminus of leukemic NPM mutants are similar, immunohistochemistry detects all exon-12 NPM mutations and is a valuable, inexpensive tool in the diagnostic-prognostic work-up of patients with AML with normal karyotype.

UR - http://www.scopus.com/inward/record.url?scp=33748703838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748703838&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-03-007013

DO - 10.1182/blood-2006-03-007013

M3 - Article

C2 - 16720834

AN - SCOPUS:33748703838

VL - 108

SP - 1999

EP - 2005

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -